Welcome To Diurnal

Diurnal is a UK-based specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.

The company has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.

Mission Statement

To address the major unmet clinical and patient needs in endocrinology by creating products for the lifelong treatment of chronic conditions.

Latest News

  • 14 Jan
    2021

    Business and trading update

    Continued growth in Alkindi sales despite impact of Covid-19 on hospital visits and new launches

    Read More

  • 14 Jan
    2021

    Licencing agreement with Eton Pharmaceuticals for Alkindi® extended to Canada

    Expands Alkindi® availability outside of key European and US commercial markets

    Read More

  • 13 Jan
    2021

    Diurnal signs agreement with Er-Kim for the distribution of Alkindi® and Chronocort® in Turkey

    This agreement adds to the Company's ongoing strategy for commercialisation of its lead products by optimising market access outside of key European markets through entering marketing and distribution agreements with companies focused on niche and orphan conditions.

    Read More